Exchange Traded Concepts LLC Lowers Position in Hologic, Inc. $HOLX

Exchange Traded Concepts LLC lessened its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 46.5% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 13,488 shares of the medical equipment provider’s stock after selling 11,714 shares during the period. Exchange Traded Concepts LLC’s holdings in Hologic were worth $1,005,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. NewEdge Wealth LLC lifted its holdings in shares of Hologic by 3.8% during the third quarter. NewEdge Wealth LLC now owns 3,779 shares of the medical equipment provider’s stock worth $281,000 after purchasing an additional 138 shares during the period. Savant Capital LLC increased its holdings in Hologic by 0.9% in the 3rd quarter. Savant Capital LLC now owns 19,776 shares of the medical equipment provider’s stock worth $1,335,000 after buying an additional 170 shares during the period. UMB Bank n.a. increased its holdings in Hologic by 38.7% in the 3rd quarter. UMB Bank n.a. now owns 620 shares of the medical equipment provider’s stock worth $42,000 after buying an additional 173 shares during the period. Farther Finance Advisors LLC raised its position in Hologic by 6.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 2,712 shares of the medical equipment provider’s stock worth $183,000 after buying an additional 174 shares during the last quarter. Finally, OneDigital Investment Advisors LLC raised its position in Hologic by 3.2% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 6,105 shares of the medical equipment provider’s stock worth $412,000 after buying an additional 191 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic Stock Performance

Shares of NASDAQ:HOLX opened at $75.65 on Friday. The company has a current ratio of 4.04, a quick ratio of 3.32 and a debt-to-equity ratio of 0.48. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $75.78. The business has a 50 day moving average of $75.28 and a two-hundred day moving average of $73.60. The company has a market capitalization of $16.89 billion, a PE ratio of 31.52, a PEG ratio of 2.24 and a beta of 0.70.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Thursday, January 29th. The medical equipment provider reported $1.04 EPS for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.05). The firm had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.07 billion. Hologic had a return on equity of 19.58% and a net margin of 13.18%.Hologic’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.87 EPS. As a group, analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Analysts Set New Price Targets

HOLX has been the topic of several recent research reports. Evercore downgraded shares of Hologic from an “outperform” rating to an “in-line” rating and dropped their price objective for the company from $79.00 to $78.00 in a report on Monday, January 5th. Argus downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research report on Monday, January 12th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hologic in a report on Wednesday, January 28th. Two investment analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $78.42.

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.